Recommendations for the management of hepatitis C virus infection among people who inject drugs

Jason Grebely, Geert Robaeys, Philip Bruggmann, Alessio Aghemo, Markus Backmund, Julie Bruneau, Jude Byrne, Olav Dalgard, Jordan J. Feld, Margaret Hellard, Matthew Hickman, Achim Kautz, Alain Litwin, Andrew R. Lloyd, Stefan Mauss, Maria Prins, Tracy Swan, Martin Schaefer, Lynn E. Taylor, Gregory J. Dore

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and care. Further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWID, particularly as new interferon-free DAA treatments for HCV infection become available.

Original languageEnglish (US)
Pages (from-to)1028-1038
Number of pages11
JournalInternational Journal of Drug Policy
Volume26
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Virus Diseases
Hepacivirus
Pharmaceutical Preparations
Interferons
Antiviral Agents
Hope
Liver Diseases
Delivery of Health Care

Keywords

  • Drug users
  • Guidelines
  • HCV
  • HIV
  • Injecting
  • Injection
  • PWID

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Cite this

Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., ... Dore, G. J. (2015). Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 26(10), 1028-1038. https://doi.org/10.1016/j.drugpo.2015.07.005

Recommendations for the management of hepatitis C virus infection among people who inject drugs. / Grebely, Jason; Robaeys, Geert; Bruggmann, Philip; Aghemo, Alessio; Backmund, Markus; Bruneau, Julie; Byrne, Jude; Dalgard, Olav; Feld, Jordan J.; Hellard, Margaret; Hickman, Matthew; Kautz, Achim; Litwin, Alain; Lloyd, Andrew R.; Mauss, Stefan; Prins, Maria; Swan, Tracy; Schaefer, Martin; Taylor, Lynn E.; Dore, Gregory J.

In: International Journal of Drug Policy, Vol. 26, No. 10, 01.10.2015, p. 1028-1038.

Research output: Contribution to journalArticle

Grebely, J, Robaeys, G, Bruggmann, P, Aghemo, A, Backmund, M, Bruneau, J, Byrne, J, Dalgard, O, Feld, JJ, Hellard, M, Hickman, M, Kautz, A, Litwin, A, Lloyd, AR, Mauss, S, Prins, M, Swan, T, Schaefer, M, Taylor, LE & Dore, GJ 2015, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, vol. 26, no. 10, pp. 1028-1038. https://doi.org/10.1016/j.drugpo.2015.07.005
Grebely, Jason ; Robaeys, Geert ; Bruggmann, Philip ; Aghemo, Alessio ; Backmund, Markus ; Bruneau, Julie ; Byrne, Jude ; Dalgard, Olav ; Feld, Jordan J. ; Hellard, Margaret ; Hickman, Matthew ; Kautz, Achim ; Litwin, Alain ; Lloyd, Andrew R. ; Mauss, Stefan ; Prins, Maria ; Swan, Tracy ; Schaefer, Martin ; Taylor, Lynn E. ; Dore, Gregory J. / Recommendations for the management of hepatitis C virus infection among people who inject drugs. In: International Journal of Drug Policy. 2015 ; Vol. 26, No. 10. pp. 1028-1038.
@article{05f67433fe1147c6b39079c13561f211,
title = "Recommendations for the management of hepatitis C virus infection among people who inject drugs",
abstract = "In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and care. Further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWID, particularly as new interferon-free DAA treatments for HCV infection become available.",
keywords = "Drug users, Guidelines, HCV, HIV, Injecting, Injection, PWID",
author = "Jason Grebely and Geert Robaeys and Philip Bruggmann and Alessio Aghemo and Markus Backmund and Julie Bruneau and Jude Byrne and Olav Dalgard and Feld, {Jordan J.} and Margaret Hellard and Matthew Hickman and Achim Kautz and Alain Litwin and Lloyd, {Andrew R.} and Stefan Mauss and Maria Prins and Tracy Swan and Martin Schaefer and Taylor, {Lynn E.} and Dore, {Gregory J.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.drugpo.2015.07.005",
language = "English (US)",
volume = "26",
pages = "1028--1038",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Recommendations for the management of hepatitis C virus infection among people who inject drugs

AU - Grebely, Jason

AU - Robaeys, Geert

AU - Bruggmann, Philip

AU - Aghemo, Alessio

AU - Backmund, Markus

AU - Bruneau, Julie

AU - Byrne, Jude

AU - Dalgard, Olav

AU - Feld, Jordan J.

AU - Hellard, Margaret

AU - Hickman, Matthew

AU - Kautz, Achim

AU - Litwin, Alain

AU - Lloyd, Andrew R.

AU - Mauss, Stefan

AU - Prins, Maria

AU - Swan, Tracy

AU - Schaefer, Martin

AU - Taylor, Lynn E.

AU - Dore, Gregory J.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and care. Further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWID, particularly as new interferon-free DAA treatments for HCV infection become available.

AB - In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and care. Further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWID, particularly as new interferon-free DAA treatments for HCV infection become available.

KW - Drug users

KW - Guidelines

KW - HCV

KW - HIV

KW - Injecting

KW - Injection

KW - PWID

UR - http://www.scopus.com/inward/record.url?scp=84941805183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941805183&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2015.07.005

DO - 10.1016/j.drugpo.2015.07.005

M3 - Article

C2 - 26282715

AN - SCOPUS:84941805183

VL - 26

SP - 1028

EP - 1038

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 10

ER -